Novartis Collaboration and License Agreement ("the Novartis Agreement") - Performance Obligation (Details) - Novartis - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 - Novartis Agreement, R&D For Integrin Research Targets $ in Millions	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 0.3
Revenue, remaining performance obligation, expected timing of satisfaction	3 months